BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28027893)

  • 1. Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes.
    Latella MC; Cocchiarella F; De Rosa L; Turchiano G; Gonçalves MAFV; Larcher F; De Luca M; Recchia A
    J Invest Dermatol; 2017 Apr; 137(4):836-844. PubMed ID: 28027893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.
    Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A
    J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.
    Berthault C; Gaucher S; Gouin O; Schmitt A; Chen M; Woodley D; Titeux M; Hovnanian A; Izmiryan A
    J Invest Dermatol; 2024 Jun; 144(6):1322-1333.e13. PubMed ID: 38043638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa.
    Gache Y; Baldeschi C; Del Rio M; Gagnoux-Palacios L; Larcher F; Lacour JP; Meneguzzi G
    Hum Gene Ther; 2004 Oct; 15(10):921-33. PubMed ID: 15585108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
    Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
    JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa.
    Hong SA; Kim SE; Lee AY; Hwang GH; Kim JH; Iwata H; Kim SC; Bae S; Lee SE
    Mol Ther; 2022 Aug; 30(8):2664-2679. PubMed ID: 35690907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa.
    Murauer EM; Gache Y; Gratz IK; Klausegger A; Muss W; Gruber C; Meneguzzi G; Hintner H; Bauer JW
    J Invest Dermatol; 2011 Jan; 131(1):74-83. PubMed ID: 20720561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Minicircle Vectors Encoding COL7A1 Gene with Human Promoters for Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa.
    Wang X; Alshehri F; Manzanares D; Li Y; He Z; Qiu B; Zeng M; A S; Lara-Sáez I; Wang W
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An RNA-targeted therapy for dystrophic epidermolysis bullosa.
    Peking P; Koller U; Duarte B; Murillas R; Wolf S; Maetzig T; Rothe M; Kocher T; García M; Brachtl G; Schambach A; Larcher F; Reichelt J; Bauer JW; Murauer EM
    Nucleic Acids Res; 2017 Sep; 45(17):10259-10269. PubMed ID: 28973459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Keratinocyte-/fibroblast-targeted rescue of Col7a1-disrupted mice and generation of an exact dystrophic epidermolysis bullosa model using a human COL7A1 mutation.
    Ito K; Sawamura D; Goto M; Nakamura H; Nishie W; Sakai K; Natsuga K; Shinkuma S; Shibaki A; Uitto J; Denton CP; Nakajima O; Akiyama M; Shimizu H
    Am J Pathol; 2009 Dec; 175(6):2508-17. PubMed ID: 19893033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa.
    Goto M; Sawamura D; Ito K; Abe M; Nishie W; Sakai K; Shibaki A; Akiyama M; Shimizu H
    J Invest Dermatol; 2006 Apr; 126(4):766-72. PubMed ID: 16439972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.
    Chen M; Kasahara N; Keene DR; Chan L; Hoeffler WK; Finlay D; Barcova M; Cannon PM; Mazurek C; Woodley DT
    Nat Genet; 2002 Dec; 32(4):670-5. PubMed ID: 12426566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.
    Twaroski K; Eide C; Riddle MJ; Xia L; Lees CJ; Chen W; Mathews W; Keene DR; McGrath JA; Tolar J
    Br J Dermatol; 2019 Dec; 181(6):1247-1253. PubMed ID: 30924923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In Vivo RDEB Model.
    Turczynski S; Titeux M; Tonasso L; Décha A; Ishida-Yamamoto A; Hovnanian A
    J Invest Dermatol; 2016 Dec; 136(12):2387-2395. PubMed ID: 27498345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa.
    Wenzel D; Bayerl J; Nyström A; Bruckner-Tuderman L; Meixner A; Penninger JM
    Sci Transl Med; 2014 Nov; 6(264):264ra165. PubMed ID: 25429058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Keratinocyte cell lines derived from severe generalized recessive epidermolysis bullosa patients carrying a highly recurrent COL7A1 homozygous mutation: models to assess cell and gene therapies in vitro and in vivo.
    Chamorro C; Almarza D; Duarte B; Llames SG; Murillas R; García M; Cigudosa JC; Espinosa-Hevia L; Escámez MJ; Mencía A; Meana A; García-Escudero R; Moro R; Conti CJ; Del Río M; Larcher F
    Exp Dermatol; 2013 Sep; 22(9):601-3. PubMed ID: 23947675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa.
    Hainzl S; Peking P; Kocher T; Murauer EM; Larcher F; Del Rio M; Duarte B; Steiner M; Klausegger A; Bauer JW; Reichelt J; Koller U
    Mol Ther; 2017 Nov; 25(11):2573-2584. PubMed ID: 28800953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB.
    Georgiadis C; Syed F; Petrova A; Abdul-Wahab A; Lwin SM; Farzaneh F; Chan L; Ghani S; Fleck RA; Glover L; McMillan JR; Chen M; Thrasher AJ; McGrath JA; Di WL; Qasim W
    J Invest Dermatol; 2016 Jan; 136(1):284-92. PubMed ID: 26763448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.
    Cutlar L; Greiser U; Wang W
    Exp Dermatol; 2014 Jan; 23(1):1-6. PubMed ID: 24107073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.